|
Hemato-oncology
Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?
Jin Park, Sung Hee Lim, Se Hyung Kim, Jina Yun, Chan Kyu Kim, Sang Cheol Lee, Jong Ho Won, Dae Sik Hong, Seong Kyu Park
Korean J Intern Med. 2020;35(4):957-969. Published online April 21, 2020
Background/Aims: Immune reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT) is affected by multiple variables during the transplantation.
Methods: We assessed the clinical factors contributing to immune function reconstitution at 100 days post-allogeneic HSCT in 114 p..
|
|
|
Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation
Taeyun Kim, Yunsuk Choi, Je-Hwan Lee, Silvia Park, Jae-Sook Ahn, Joon-Ho Moon, Ho-Jin Shin, Won Sik Lee, Dajung Kim, Ho Sup Lee
Korean J Intern Med. 2020;35(2):429-437. Published online January 10, 2019
Background/Aims: Rabbit anti-thymocyte globulin (ATG) is usually incorporated in hematopoietic stem cell transplantation (HSCT) to reduce the incidence of graft-versus-host disease (GVHD). This study aimed to find optimal ATG doses in patients undergoing human leukocyte antigen (HLA)-mismatched allo..
|
|
|
A confusing case of multiple sclerosis and central nervous system graft versus host disease
Byung-Nam Yoon, Choong Kun Ha, Kwang-Woo Lee, Sung-Hye Park, Jung-Joon Sung
Korean J Intern Med. 2016;31(5):995-998. Published online February 3, 2016
|
|
|
Hemato-oncology
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Young Sok Ji, Min Sung Lee, Chang Wook Min, Seong Kyu Park, Se Hyung Kim, Jina Yun, Hyun Jung Kim, Kyoung Ha Kim, Chan Kyu Kim, Kyu-Taek Lee, Jong-Ho Won, Dae Sik Hong
Korean J Intern Med. 2016;31(4):750-761. Published online March 28, 2016
Background/Aims: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and c..
|
|
|
Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation
Joo Han Park, Hyo Jung Lee, Sei Rhan Kim, Ga Won Song, Seung Kyong Lee, Sun Young Park, Ki Chan Kim, Sun Hyuk Hwang, Joon Seong Park
Korean J Intern Med. 2014;29(5):630-636. Published online August 28, 2014
Background/Aims: The treatment for steroid-refractory acute graft versus host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) needs to be standardized. We report our clinical experience with etanercept for steroid-refractory acute GVHD.
Methods: Eighteen patients who underwent ..
|
|
|
Clinical applications of mesenchymal stem cells
Nayoun Kim, Seok-Goo Cho
Korean J Intern Med. 2013;28(4):387-402. Published online July 1, 2013
Mesenchymal stem cells (MSCs) are self-renewing, multipotent progenitor cells with multilineage potential to differentiate into cell types of mesodermal origin, such as adipocytes, osteocytes, and chondrocytes. In addition, MSCs can migrate to sites of inflammation and exert potent immunosuppress..
|
|
|
